Drug Profile
Research programme: interleukin-1 receptor-associated kinase 4 inhibitors - Ligand Pharmaceuticals/TG Therapeutics
Alternative Names: IRAK-4 inhibitors - Ligand Pharmaceuticals/TG Therapeutics; LG-0224912Latest Information Update: 28 Mar 2021
Price :
$50
*
At a glance
- Originator Ligand Pharmaceuticals
- Developer Ligand Pharmaceuticals; TG Therapeutics Inc
- Class Anti-inflammatories; Antineoplastics; Antirheumatics; Small molecules
- Mechanism of Action Interleukin-1 receptor-associated kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Arthritis; Autoimmune disorders; Cancer; Inflammation
Most Recent Events
- 28 Mar 2021 No recent reports of development identified for preclinical development in Autoimmune-disorders in USA (PO)
- 28 Mar 2021 No recent reports of development identified for preclinical development in Cancer in USA (PO)
- 14 Mar 2019 Interleukin-1 receptor-associated kinase 4 inhibitors is still in preclinical trials for Cancer and Autoimmune disorders in USA (Ligand Pharmaceuticals and TG Therapeutics pipeline, March 2019)